Comparative Analysis of Complicated Urinary Tract Infections Caused by Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> and Extended-Spectrum β-Lactamase-Producing <i>Klebsiella pneumoniae</i>
Elena Sendra,
Inmaculada López Montesinos,
Alicia Rodriguez-Alarcón,
Juan Du,
Ana Siverio-Parés,
Mar Arenas-Miras,
Esperanza Cañas-Ruano,
Nuria Prim,
Xavier Durán-Jordà,
Fabiola Blasco-Hernando,
Enric García-Alzorriz,
Francesc Cots,
Olivia Ferrández,
Silvia Gómez-Zorrilla
Affiliations
Elena Sendra
Infectious Diseases Service, Hospital del Mar, Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain
Inmaculada López Montesinos
Infectious Diseases Service, Hospital del Mar, Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain
Alicia Rodriguez-Alarcón
Pharmacy Service, Hospital del Mar, Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain
Juan Du
Infectious Diseases Service, Hospital del Mar, Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain
Ana Siverio-Parés
Microbology Service, Laboratori de Referència de Catalunya, Hospital del Mar, 08003 Barcelona, Spain
Mar Arenas-Miras
Infectious Diseases Service, Hospital del Mar, Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain
Esperanza Cañas-Ruano
Infectious Diseases Service, Hospital del Mar, Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain
Nuria Prim
Microbology Service, Laboratori de Referència de Catalunya, Hospital del Mar, 08003 Barcelona, Spain
Xavier Durán-Jordà
Methodology and Biostatistics Support Unit, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), 08003 Barcelona, Spain
Fabiola Blasco-Hernando
Infectious Diseases Service, Hospital del Mar, Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain
Enric García-Alzorriz
Management Control Department, Hospital del Mar-Parc de Salut Mar, 08003 Barcelona, Spain
Francesc Cots
Management Control Department, Hospital del Mar-Parc de Salut Mar, 08003 Barcelona, Spain
Olivia Ferrández
Pharmacy Service, Hospital del Mar, Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain
Silvia Gómez-Zorrilla
Infectious Diseases Service, Hospital del Mar, Infectious Pathology and Antimicrobials Research Group (IPAR), Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Universitat Autònoma de Barcelona (UAB), Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain
The objective was to compare clinical characteristics, outcomes, and economic differences in complicated urinary tract infections (cUTI) caused by extensively drug-resistant Pseudomonas aeruginosa (XDR P. aeruginosa) and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae (ESBL-K. pneumoniae). A retrospective study was conducted at a tertiary care hospital. Patients with XDR P. aeruginosa and ESBL-K. pneumoniae cUTIs were compared. The primary outcome was clinical failure at day 7 and at the end of treatment (EOT). Secondary outcomes: 30- and 90-day mortality, microbiological eradication, and economic cost. Two-hundred and one episodes were included, of which 24.8% were bloodstream infections. Patients with XDR P. aeruginosa cUTI more frequently received inappropriate empirical therapy (p P. aeruginosa group (26.7%). ESBL-K. pneumoniae cUTI was associated with worse eradication rates, higher recurrence, and higher infection-related readmission. In multivariate analysis, XDR P. aeruginosa was independently associated with clinical failure on day 7 of treatment (OR 4.34, 95% CI 1.71–11.04) but not at EOT, or with mortality. Regarding hospital resource consumption, no significant differences were observed between groups. XDR P. aeruginosa cUTI was associated with worse early clinical cures and more antibiotic side effects than ESBL-K. pneumoniae infections. However, no differences in mortality or in hospitalization costs were observed.